SCHEMBL4675007

SCHEMBL4675007

O=C(O)C(O)=CC(=O)c1ccn(S(=O)(=O)c2ccc(Cl)cc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 0.44
AKR1C1 Q04828 2/20 0.44
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 3/20 0.36
CNKSR1 Q969H4 1/20 0.35
AKR1C2 P52895 1/20 0.35
GRM4 Q14833 1/20 0.35
ALOX15 P16050 2/20 0.35
USP2 O75604 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD11B1 P28845 1/20 0.34
MAPT P10636 2/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677344 0.88 AKR1C3 (0.50) AKR1C3AKR1C1KMT2AHTTSMN1; SMN2
SCHEMBL4672324 0.87 AKR1C3 (0.44) AKR1C3AKR1C1HTTSMN1; SMN2CYP3A4
SCHEMBL4674101 0.79 AKR1C3 (0.38) AKR1C3AKR1C1KMT2AMEN1HTT
SCHEMBL4679719 0.79 AKR1C3 (0.38) AKR1C3AKR1C1KMT2AMEN1HTT
SCHEMBL7236361 0.79 TSHR (0.35) AKR1C3AKR1C1KMT2AMEN1HTT
SCHEMBL7236366 0.79 TSHR (0.35) AKR1C3AKR1C1KMT2AMEN1HTT
SCHEMBL4674580 0.76 ALDH1A1 (0.39) AKR1C3AKR1C1KMT2AMEN1SMN1; SMN2
SCHEMBL9801780 0.74 AKR1C3 (0.49) AKR1C3AKR1C1KMT2AMEN1HTT
SCHEMBL4672360 0.73 RAPGEF4 (0.47) AKR1C3AKR1C1SMN1; SMN2ALDH1A1AKR1C2
SCHEMBL4677989 0.73 ALDH1A1 (0.63) AKR1C3AKR1C1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AKR1C3 30/4885AKR1C1 25/4885KMT2A 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.